Le Lézard
Classified in: Health
Subject: SVY

The radiodermatitis treatment market will register a CAGR of over 4% by 2023

NEW YORK, May 21, 2019 /PRNewswire/ -- About this market

Several rising initiatives by research institutes are impacting the radiodermatitis treatment market growth during the forecast period. Existing vendors are further striving to evaluate the therapeutic efficacy of a wide range of radiodermatitis treatment products for leveraging their product portfolio. Researchers from different universities are using low-intensity laser therapy in breast cancer patients for preventing and controlling the symptoms of this health condition. As a result, initiatives by several research institutes will lead to the radiodermatitis treatment market growth during the forecast period. Analysts have predicted that the radiodermatitis treatment market will register a CAGR of over 4% by 2023.

Read the full report: https://www.reportlinker.com/p05777290/?utm_source=PRN

Market Overview

The rising number of public and private healthcare organizations

Promoting awareness about radiodermatitis diagnosis and treatment and increasing the adoption of radiodermatitis products. This will drive the growth of the market during the forecast period.

Advent of novel radiation equipment with fewer side-effects

The global radiodermatitis treatment market is currently witnessing the advent of novel radiation equipment with fewer side-effects, leading to a decrease in demand for radiodermatitis drugs, thereby hindering the market growth.

For the detailed list of factors that will drive and challenge the growth of the radiodermatitis treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Several vendors are focusing on the concept of moisture therapy, which involves moisturizing the wound area to promote natural cell repair while giving the injured cells sufficient time to recover. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05777290/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


SOURCE Reportlinker

These press releases may also interest you

at 06:59
Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Administration ("FDA') regarding its New Drug...

at 06:55
NantHealth, Inc. , a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020, after market close. NantHealth management will host...

at 06:45
Midwives Elizabeth Brandeis and Liz Fraser, alongside human rights lawyer Mary Cornish, will present and respond to new orders from the Human Rights Tribunal of Ontario to the Ford government. In Ontario, the Human Rights Code protects against...

at 06:38
Elsevier, a global leader in information analytics specializing in science and health, is making Embase, its biomedical database, available to Research4Life with immediate effect. Elsevier is a founding partner of Research4Life, a public-private...

at 06:35
Sage Therapeutics , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Cowen & Co....

at 06:35
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will present a company overview at...

News published on 21 may 2019 at 19:02 and distributed by: